Delving into the Latest Updates on Guangzhou Yipinhong Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Nervous System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Herbal medicine

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Nervous System Diseases	2
Infectious Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Herbal medicine	1
Chemical drugs	1

Top 5 Target	Count

VDCCs(Voltage-gated calcium channel)	1
URAT1(Uric acid transporter 1)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
L-type calcium channel(Voltage-gated L-type calcium channel)	1

（1）主要目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）药代动力学的影响；（2）次要目的：评价广州瑞安博医药科技有限公司研制的AR882胶囊（规格：25 mg）在中国健康受试者中的安全性和耐受性；（3）探索性目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）的药效动力学的影响。

[Translation]

(1) Primary objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacokinetics of AR882 capsules (specification: 25 mg); (2) Secondary objective: To evaluate the safety and tolerability of AR882 capsules (specification: 25 mg) developed by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. in healthy Chinese subjects; (3) Exploratory objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacodynamics of AR882 capsules (specification: 25 mg).

Start Date23 Sep 2023

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

[+1]

CTR20230976 / CompletedNot Applicable

苯磺酸氨氯地平片在健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A single-center, open-label, randomized, single-dose, two-period, double-crossover bioequivalence study of amlodipine besylate tablets in healthy subjects under fasting and fed conditions

主要目的比较空腹和餐后给药条件下，广州一品红制药有限公司生产的苯磺酸氨氯地平片（10 mg（按C20H25ClN2O5计））与辉瑞制药有限公司持证的苯磺酸氨氯地平片（10 mg，商品名：络活喜®（Norvasc®））在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的评价空腹和餐后给药条件下，广州一品红制药有限公司生产的苯磺酸氨氯地平片（10 mg（按C20H25ClN2O5计））与辉瑞制药有限公司持证的苯磺酸氨氯地平片（10 mg，商品名：络活喜®（Norvasc®））的安全性。

[Translation]

Main objective To compare the differences in the extent and rate of absorption of amlodipine besylate tablets (10 mg (calculated as C20H25ClN2O5)) produced by Guangzhou Yipinhong Pharmaceutical Co., Ltd. and amlodipine besylate tablets (10 mg, trade name: Norvasc®) certified by Pfizer Pharmaceutical Co., Ltd. in healthy adults under fasting and fed administration conditions, and to evaluate their bioequivalence. Secondary objective To evaluate the safety of amlodipine besylate tablets (10 mg (calculated as C20H25ClN2O5)) produced by Guangzhou Yipinhong Pharmaceutical Co., Ltd. and amlodipine besylate tablets (10 mg, trade name: Norvasc®) certified by Pfizer Pharmaceutical Co., Ltd. under fasting and fed administration conditions.

Start Date07 May 2023

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

CTR20230351 / CompletedPhase 1

AR882胶囊在健康受试者中单中心、随机、开放、单剂量、双周期、双交叉空腹状态下的相对生物利用度试验

[Translation] A single-center, randomized, open-label, single-dose, two-period, double-crossover relative bioavailability study of AR882 capsules in healthy subjects under fasting conditions

（1）主要目的：在空腹给药条件下，比较广州瑞安博医药科技有限公司研制的AR882胶囊（规格：25 mg）与BioDuro LLC生产的AR882胶囊（规格：25 mg）在中国健康成年人群中吸收程度和速度的差异，评价其相对生物利用度。（2）次要目的：评价广州瑞安博医药科技有限公司研制的AR882胶囊（规格：25 mg）在中国健康受试者中的安全性和耐受性。（3）探索性目的：研究中国健康受试者口服AR882胶囊（规格：25 mg）后的药效动力学（PD）特征。

[Translation]

(1) Primary objective: To compare the differences in the extent and rate of absorption of AR882 capsules (specification: 25 mg) developed by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. and AR882 capsules (specification: 25 mg) produced by BioDuro LLC in healthy Chinese adults under fasting conditions, and to evaluate their relative bioavailability. (2) Secondary objective: To evaluate the safety and tolerability of AR882 capsules (specification: 25 mg) developed by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. in healthy Chinese subjects. (3) Exploratory objective: To study the pharmacodynamic (PD) characteristics of AR882 capsules (specification: 25 mg) after oral administration in healthy Chinese subjects.

Start Date24 Feb 2023

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Login to view more data

3

Literatures (Medical) associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Heilongjiang Yiyao

Process conditions screening of Compound Amino Acid Injection (18AA)

Author: Zhuang, Manxian ; Zhou, Cuilan

Objective: To establish the process conditions which are suitable for the large-scale production of Compound Amino Acid Injection (18AA), and to ensure the stability of product quality.Methods: Through the screening of the production process conditions which can affect the quality of Compound Amino Acid Injection (18AA), and to determine the conditions of the optimal dosage of activated carbon, sterilization time, sterilization temperature and whether nitrogen.Results: The optimal conditions were as follow: filled with nitrogen, the activated carbon dosage of 0.05%, the sterilization temperature of 121°C and the sterilization time of 10 min.Conclusions: The established process conditions are suitable for the production of this product, which is reasonable and scientific.

Guangdong Huagong

Study on the Inclusion Process of Volatile Oil in Qinxiang Qingjie Oral Liquid

Author: Kang Xiaodong ; Zhang Chongjing ; Li Minghui ; Li Yongwei ; Li Haibo

Objective: To study the best inclusion process of the pogostemon cablin essential oil from Qinxiang Qingjie oral liquid with hydroxypropyl betacyl dextrin(HP-β-CD).Methods: The process conditions were screened by determining the inclusion rate of volatile oils and the yield of inclusion compoundOrthogonal design test was used to optimize the inclusion process, and the structure of the inclusion compound was characterized by GC, X-ray diffraction and IR.Results: the best preparation process of inclusion compound was as follows: the inclusion temperature was 35 °C, the inclusion time was 2.5 h, and the volatile oil of patchouli♂HP-β-CD=1♂12.The inclusion compound was formed and the composition of the volatile oil had no obvious change after inclusion.Conclusion: According to the optimized process, The complex prepared under the optimized process is stable, and that has the advantages of the highest inclusion rate, stable inclusion process and easily soluble in oral liquid

Zhongyao Xinyao Yu Linchuang Yaoli

Determination of ephedrine hydrochloride and pseudoephedrine hydrochloride in Fuganlin oral liquid by HPLC

Author: Zhang, Li ; Chen, Yiwen ; Zeng, Xiaoyan ; Zeng, Yongchang

Objectives: To establish a HPLC method to determine the content of ephedrine hydrochloride and pseudoephedrine hydrochloride in Fuganlin oral liquidMethods: The chromatog. conditions was as follows: Phenomenex Synergi Polar-RP column (250 mm × 4.6 mm, 4μm), methanol-0.092% phosphoric acid solution (containing 0.04% triethylamine and 0.02% di-n-butylamine) (1.5:98.5) as the mobile phase, flow rate being 1.0 mL · min^-1, detection wavelength set as 210 nm.Results: The linear range of ephedrine hydrochloride and pseudoephedrine hydrochloride was 1-100μg · mL^-1, and the average recovery (n = 6) was 97.43% (RSD = 0.80%) and 98.59% (RSD = 1.77%) resp.Conclusions: The method is simple, accurate and reliable, and can be used for the simultaneous determination of ephedrine hydrochloride and pseudoephedrine hydrochloride, which will provide a scientific basis for quality evaluation of Fuganlin oral liquid

100 Deals associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 3 Clinical

NDA/BLA

1

2

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Amlodipine Besylate ( L-type calcium channel )	Coronary Artery Disease More	Approved
QinXiangQingJie	Respirovirus Infections More	Approved
Amlodipine Benzoate ( VDCCs )	Angina Pectoris More	NDA/BLA
Pozdeutinurad ( URAT1 )	Hyperuricemia More	Phase 3 Clinical
APH01727 ( GLP-1R )	Diabetes Mellitus, Type 2 More	Phase 1